| Report ID | Date of report | Patient age | Patient gender |
| 48054 | Feb, 17, 2006 | 69 | Male |
List of drugs the patient takes:
| Drug | Ingredient(s) |
Vioxx | rofecoxib |
Tylenol | acetaminophen |
Zestril | lisinopril |
| Name |
Angina Pectoris |
Arthralgia |
Back Pain |
Cardiac Disorder |
Chest Pain |
Coronary Artery Disease |
Coronary Artery Restenosis |
Cough |
Dyslipidaemia |
Dyspepsia |
Dyspnoea |
Dyspnoea Exertional |
Flatulence |
Hypertension |
Ischaemic Cardiomyopathy |
Lung Squamous Cell Carcinoma Stage Unspecified |
Musculoskeletal Chest Pain |
Myocardial Infarction |
Pleurisy |
Pneumonia |
Pulmonary Mass |
Renal Failure Chronic |
Transient Ischaemic Attack |
Upper Respiratory Tract Infection |
Results from eHealthMe : 553 report(s)
Comparison with the patient:
| Name | Count (% of total reports) |
Angina Pectoris | 46 (8.32%) |
Arthralgia | 86 (15.55%) |
Back Pain | 25 (4.52%) |
Cardiac Disorder | 45 (8.14%) |
Chest Pain | 61 (11.03%) |
Coronary Artery Disease | 127 (22.97%) |
Coronary Artery Restenosis | 2 (0.36%) |
Cough | 13 (2.35%) |
Dyslipidaemia | 6 (1.08%) |
Dyspepsia | 19 (3.44%) |
Dyspnoea | 45 (8.14%) |
Dyspnoea Exertional | 15 (2.71%) |
Flatulence | 73 (13.20%) |
Hypertension | 150 (27.12%) |
Ischaemic Cardiomyopathy | 51 (9.22%) |
Lung Squamous Cell Carcinoma Stage Unspecified | 2 (0.36%) |
Musculoskeletal Chest Pain | 6 (1.08%) |
Myocardial Infarction | 121 (21.88%) |
Pleurisy | 2 (0.36%) |
Pneumonia | 48 (8.68%) |
Pulmonary Mass | 74 (13.38%) |
Renal Failure Chronic | 77 (13.92%) |
Transient Ischaemic Attack | 55 (9.95%) |
Upper Respiratory Tract Infection | 9 (1.63%) |
Top 3 (total: 395. Click here to see more) co-used drugs - potential interacting drugs:
| Name | Count (% of total co-drugs) |
Prinivil | 264 (2.93%) |
Humulin N | 216 (2.40%) |
Norvasc | 198 (2.20%) |
Death reported: 21 (3.80% of total reports)
| Name | Count (% of total reports) |
Cardiac Failure Congestive | 193 (34.90%) |
Cerebrovascular Accident | 181 (32.73%) |
Hypertension | 150 (27.12%) |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Recent drug risk analysis reports:
